Triglyceride variability and risk of heart failure events in type 2 diabetes: Results from the ACCORD trial

Documenti analoghi

• Obesity and overweight‐related differences in cardiometabolic risk factors in type 1 diabetes
  di: Adnan S. Syed, et al.
  Pubblicazione: (2025)
• Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes
  di: Julian W. Sacre, et al.
  Pubblicazione: (2026)
• Longitudinal exposure to non‐ HDL ‐C and cardiovascular events, all‐cause mortality in type 2 diabetes: A post hoc analysis of the ACCORD trial
  di: Yueyue Wang, et al.
  Pubblicazione: (2026)
• Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
  di: Abderrahim Oulhaj, et al.
  Pubblicazione: (2024)
• Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
  di: Alex E. Henney, et al.
  Pubblicazione: (2024)